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During pregnancy the maternal pancreatic islets of Langerhans undergo adaptive changes
to compensate for gestational insulin resistance. Kisspeptin has been shown to stimulate
insulin release, through its receptor, GPR54. The placenta releases high levels of
kisspeptin into the maternal circulation, suggesting a role in modulating the islet adaptation
to pregnancy. In the present study we show that pharmacological blockade of endogenous
kisspeptin in pregnant mice resulted in impaired glucose homeostasis. This glucose
intolerance was due to a reduced insulin response to glucose as opposed to any effect on
insulin sensitivity. A b cell–specific GPR54-knockdown mouse line was found to exhibit
glucose intolerance during pregnancy, with no phenotype observed outside of pregnancy.
Furthermore, in pregnant women circulating kisspeptin levels significantly correlated with
insulin responses to oral glucose challenge and were significantly lower in women with
gestational diabetes (GDM) compared with those without GDM. Thus, kisspeptin represents
a placental signal that plays a physiological role in the islet adaptation to pregnancy,
maintaining maternal glucose homeostasis by acting through the b cell GPR54 receptor.
Our data suggest reduced placental kisspeptin production, with consequent impaired
kisspeptin-dependent b cell compensation, may be a factor in the development of GDM in
humans.
Research Article Endocrinology Reproductive biology
Find the latest version:
http://jci.me/124540/pdf
1insight.jci.org   https://doi.org/10.1172/jci.insight.124540
R E S E A R C H  A R T I C L E
Authorship note: JEB and TGH 
contributed equally to this study.
Conflict of interest: The authors have 
declared that no conflict of interest 
exists.
Submitted: August 28, 2018 
Accepted: September 11, 2019 
Published: October 17, 2019.
Reference information: JCI Insight. 
2019;4(20):e124540. 
https://doi.org/10.1172/jci.
insight.124540.
A role for placental kisspeptin in β cell 
adaptation to pregnancy
James E. Bowe, Thomas G. Hill, Katharine F. Hunt, Lorna I.F. Smith, Sian J.S. Simpson,  
Stephanie A. Amiel, and Peter M. Jones
School of Life Course Sciences, King’s College London, London, United Kingdom.
Introduction
Kisspeptins are a family of  peptides, encoded by the KISS1 gene, which are the endogenous ligands for 
the Gq-protein–coupled receptor GPR54, also commonly known as KISS1R. Kisspeptin is well known for 
its permissive role acting locally in the hypothalamus to regulate puberty and reproductive function (1, 2), 
but its role in other physiological systems is much less understood. GPR54 is highly expressed in several 
peripheral tissues (3), including insulin-secreting pancreatic β cells (4), consistent with a role for kisspeptin 
in regulating glucose homeostasis (4). However, there are discrepancies in the literature about the effects of  
exogenous kisspeptin on β cell function. We have previously reported that exogenous kisspeptin enhances 
glucose-induced insulin secretion from rodent, porcine, and human islets in vitro (5, 6), and in rats and 
mice in vivo (7), consistent with other reports of  stimulatory effects in vitro (8) and in vivo in non-human 
primates (9) and in humans (10). However, others report predominantly inhibitory effects in vitro (11, 12). 
Similarly, studies investigating the physiological role(s) of  endogenous kisspeptin in glucose homeostasis 
are seemingly contradictory. Thus, it has been suggested that low levels of  hepatic kisspeptin are released 
to impair β cell function and play a role in the development of  type 2 diabetes (13), while GPR54-null mice 
become glucose intolerant, consistent with stimulatory effects of  kisspeptin on β cell function (14, 15). 
Aspects of  the metabolic phenotype may also be sex specific because female GPR54-null mice develop 
increased adiposity and impaired glucose tolerance that are not observed in males (16).
Circulating kisspeptin levels are extremely low under most physiological circumstances. The exception 
is in pregnancy, when kisspeptin is released from the placenta into the maternal circulation such that circu-
lating levels increase several thousand–fold in humans (17). The circulating kisspeptin during pregnancy in 
animal models is unclear because of  the lack of  reliable assays; however, kisspeptin mRNA is expressed in 
rodent placenta and increases through pregnancy (18–20). Thus, one potential physiological role for β cell 
GPR54 is in regulating β cell adaptive responses to pregnancy. Pregnancy presents the maternal metabo-
lism with the problem of  providing for the energy requirements of  the growing fetus while maintaining fuel 
homeostasis in the mother. In both rodents and humans, there are reversible adaptive changes, including 
a progressive increase in maternal insulin resistance, which, under normal circumstances, is countered by 
During pregnancy the maternal pancreatic islets of Langerhans undergo adaptive changes to 
compensate for gestational insulin resistance. Kisspeptin has been shown to stimulate insulin 
release, through its receptor, GPR54. The placenta releases high levels of kisspeptin into the 
maternal circulation, suggesting a role in modulating the islet adaptation to pregnancy. In the 
present study we show that pharmacological blockade of endogenous kisspeptin in pregnant 
mice resulted in impaired glucose homeostasis. This glucose intolerance was due to a reduced 
insulin response to glucose as opposed to any effect on insulin sensitivity. A β cell–specific 
GPR54-knockdown mouse line was found to exhibit glucose intolerance during pregnancy, with no 
phenotype observed outside of pregnancy. Furthermore, in pregnant women circulating kisspeptin 
levels significantly correlated with insulin responses to oral glucose challenge and were significantly 
lower in women with gestational diabetes (GDM) compared with those without GDM. Thus, 
kisspeptin represents a placental signal that plays a physiological role in the islet adaptation to 
pregnancy, maintaining maternal glucose homeostasis by acting through the β cell GPR54 receptor. 
Our data suggest reduced placental kisspeptin production, with consequent impaired kisspeptin-
dependent β cell compensation, may be a factor in the development of GDM in humans.
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increased maternal insulin secretion to maintain normoglycemia. The increased insulin secretory capacity 
is provided through both functional and structural changes to the islets (21). Failure of  these compensato-
ry mechanisms may result in the development of  glucose intolerance in pregnancy, known as gestational 
diabetes mellitus (GDM) in humans (22). At present our understanding of  the signals regulating β cell 
adaptations to pregnancy is incomplete. Previous studies have demonstrated a role for prolactin and pla-
cental lactogens (23, 24), but lactogenic hormones alone are unlikely to account for all the β cell adaptive 
responses. The timing of  their increased secretion does not mirror that of  the adaptive responses, and there 
is interest in identifying other contributing signals. Placental production of  kisspeptin, and the consequent 
increased level of  kisspeptin in the maternal circulation, closely reflect the time course of  the increased 
insulin secretory capacity of  maternal β cells (25, 26).
We here demonstrate that placental kisspeptin acts as an important signal to amplify insulin secretory 
responses as needed to compensate for increased insulin resistance during pregnancy. We show that, in 
experimental animals, pharmacological blockade or genetic ablation of  β cell GPR54 during pregnancy 
results in a failure of  normal homeostatic mechanisms and the consequent development of  maternal glu-
cose intolerance. Furthermore, we demonstrate that low circulating levels of  kisspeptin during human preg-
nancy are associated with GDM. Therefore, placental kisspeptin acting via β cell GPR54 is essential for 
normal glucose homeostasis during pregnancy.
Results
Effects of  pharmacological activation or blockade of  GPR54 on glucose homeostasis. Chronic activation of  GPR54 
improved glucose tolerance and insulin secretion in mice, consistent with a role for circulating kisspeptin 
in glucose homeostasis. Thus, kisspeptin administration to nonpregnant mice for 8 days resulted in a sig-
nificant improvement in glucose tolerance as assessed by an intraperitoneal glucose tolerance test, with 
significant reductions in blood glucose at 15–30 minutes after administration (Figure 1A). However, this 
was not reflected in the overall area under the curve (AUC) data (Figure 1B) because blood glucose levels 
were similar in both treatment groups from 60 to 120 minutes. The difference in glucose profile was asso-
ciated with significantly elevated plasma insulin levels in kisspeptin-treated mice 30 minutes after glucose 
administration, while basal insulin levels were not altered (Figure 1C). There were no significant differ-
ences in plasma glucose between treatment groups in an insulin tolerance test (Figure 1, D and E). Thus, 
circulating kisspeptin enhances β cell secretory responses to glucose challenge.
Pharmacological blockade of  GPR54 caused impaired insulin secretion and impaired glucose tol-
erance in pregnant mice, as shown in Figure 2. Pregnancy in ICR mice is associated with impaired glu-
cose tolerance and increased insulin resistance at both days 10–12 and days 16–18 of  pregnancy when 
compared with nonpregnant controls (Supplemental Figure 1, A–C; supplemental material available 
online with this article; https://doi.org/10.1172/jci.insight.124540DS1), and this was associated with 
enhanced glucose-induced insulin secretion, as assessed by significantly higher plasma insulin levels in 
the pregnant mice 30 minutes after a glucose load (Figure 2B). Chronic administration of  the GPR54 
antagonist kisspeptin-234 to pregnant mice further impaired glucose tolerance by day 18 of  pregnancy 
(Figure 2, A and B), which was associated with significant reductions in glucose-stimulated insulin 
secretion (Figure 2C) but without any effect on basal plasma insulin levels (Figure 2C). Blocking 
endogenous kisspeptin by antagonist administration had no detectable effects on the pregnancy-depen-
dent increases in insulin resistance observed at either mid-pregnancy (day 12) or late pregnancy (day 
18) (Figure 2, D and E). Thus, blocking activation of  GPR54 by endogenous kisspeptin during preg-
nancy induces glucose intolerance by reducing glucose-induced insulin secretion rather than through 
effects on insulin target tissues.
Effects of  β cell GPR54 deletion on in vitro islet function. To assess whether the metabolic effects of  phar-
macological blockade of  GPR54 were mediated primarily through β cells, we generated a β cell–specific 
GPR54-knockout mouse model (β cell GPR54–/–). Successful β cell–specific knockdown of  GPR54 was 
confirmed and the model validated (Supplemental Figures 2 and 3). Before in vivo experiments islets from 
β cell GPR54–/– mice were isolated for in vitro characterization.
For studies in β cell GPR54–/– mice, 3 control groups were potentially necessary: Cre+ mice not 
administered tamoxifen (Cre+/TMX–), Cre– mice administered tamoxifen (Cre–/TMX+), and Cre – mice 
not administered tamoxifen (Cre–/TMX–). There was no difference in insulin content between β cell 
GPR54–/– mice and any of  these control groups (Cre+/TMX–, Cre–/TMX+, and Cre–/TMX–; Figure 3A). 
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For subsequent in vitro characterization the Cre+/TMX– group was used because the presence of  the Cre 
gene was more likely to represent a confounding factor in terms of  islet function. In static incubation 
experiments there was no significant difference between β cell GPR54–/– and Cre+/TMX– islets in glu-
cose-stimulated insulin secretion across a physiological range of  glucose concentrations from 5 to 11 mM 
glucose (Figure 3B). Similarly, in perifusion experiments there was no difference in basal insulin secre-
tion at 2 mM glucose or in the first- or second-phase insulin response to a maximally stimulating glucose 
concentration (20 mM; Figure 3, C and D). In Cre+/TMX– islets the addition of  1 μM kisspeptin-10 also 
resulted in a significant potentiation of  glucose-stimulated insulin secretion, which was sustained for the 
duration of  kisspeptin exposure. In contrast, β cell GPR54–/– islets showed an initial stimulatory insulin 
response to kisspeptin, but this effect was brief; kisspeptin was unable to maintain a prolonged potentiat-
ing effect (Figure 3, C and D).
Effects of  deletion of  β cell GPR54 on glucose homeostasis in vivo. Having confirmed normal glucose respon-
siveness, but impaired kisspeptin response, in β cell GPR54–/– islets, the mice were used to assess whole-
body glucose homeostasis. GPR54 ablation in β cells had no significant effects in nonpregnant mice, as 
shown in Figure 4, A–C. Thus, virgin female β cell GPR54–/– mice showed no significant differences in 
glucose tolerance (Figure 4A), glucose-induced insulin secretion (Figure 4B), or insulin resistance (Fig-
ure 4C) when compared to any of  the 3 control groups (Cre+/TMX–, Cre–/TMX+, and Cre–/TMX–). In 
addition, we did not detect any significant differences in glucose tolerance, circulating insulin, or insulin 
sensitivity (Figure 4, A–C) between any of  the control groups, suggesting that neither the presence of  the 
Cre transgene nor the use of  TMX as an activator had any significant effect on glucose homeostasis in this 
experimental model.
Figure 1. In vivo effects of chronic kisspeptin administration on 
glucose homeostasis in nonpregnant mice. (A) In nonpregnant female 
ICR mice, chronic subcutaneous administration of kisspeptin result-
ed in improved glucose tolerance after intraperitoneal (i.p.) glucose 
administration (2 g/kg) when compared with untreated controls (2-way 
repeated-measures ANOVA, 15 minutes P < 0.001). (B) There was no sig-
nificant difference in overall 120 minutes area under the curve (AUC), but 
kisspeptin treatment did result in a significant reduction in glucose AUC 
over 0–60 minutes (2-tailed Student’s t test, P = 0.0321). (C) Although 
chronic kisspeptin treatment had no significant effect on fasting plasma 
insulin levels, kisspeptin-treated animals had significantly increased 
insulin release in response to i.p. glucose administration (2 g/kg) after 
30  minutes when compared with controls (1-way ANOVA, P = 0.033). (D) 
Kisspeptin had no effect on the plasma glucose response to i.p. insulin 
administration (0.75  IU/kg) when compared to controls, through com-
parison of both individual time points and (E) glucose AUC. Mean ± SEM, 
n = 11–12, and *P < 0.05 vs. control.
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However, the β cell GPR54–/– mouse model confirmed the importance of  kisspeptin signaling in β 
cell adaptive responses to pregnancy, as shown in Figure 4, D–H. Thus, by day 16 of  pregnancy β cell 
GPR54–/– mice had significantly impaired glucose tolerance when compared with controls (Figure 4, 
D and E), and this was associated with reduced insulin secretory responses 30 minutes after a glucose 
challenge (Figure 4F), although basal plasma insulin levels were unaffected by the β cell GPR54 dele-
tion (Figure 4F). In accordance with the studies using the kisspeptin antagonist in pregnant mice (Fig-
ure 2, D and E), pregnant β cell GPR54–/– mice showed no significant differences in insulin resistance 
(Figure 4, G and H) or in body weight when compared to controls (Supplemental Figure 4A). Thus, 
deletion of  β cell GPR54 induces glucose intolerance in pregnancy by reducing glucose-induced insu-
lin secretion, consistent with placental kisspeptin acting to compensate for pregnancy-induced insulin 
resistance by enhancing β cell function.
Effects of  deletion of  β cell GPR54 on pregnant β cell mass. Pregnant mice were administered BrdU from 
days 10–18 of  pregnancy to label proliferating cells before pancreas samples being collected at day 18. The 
percentage of  BrdU+ β cells was significantly reduced in β cell GPR54–/– mice compared with Cre+/TMX– 
controls, demonstrating an attenuation of  the rapid β cell proliferation normally observed during late preg-
nancy (Figure 5, A–C). Despite the change in β cell proliferation, there was no significant difference in islet 
cross-sectional area between day 18 pregnant β cell GPR54–/– mice and Cre+/TMX– controls (Figure 5D).
Rodent pregnancy is also associated with β cell hypertrophy, so the mean individual β cell area was 
calculated as total β cell area divided by number of  β cell nuclei. This may slightly overestimate individual 
β cell area because not all β cell nuclei may be visualized in a given section, but it is still a useful measure 
for comparing changes in individual β cell area between treatment groups. No significant difference was 
Figure 2. Effects of kisspeptin-234 on glucose homeostasis during pregnancy in mice. (A) At day 10 of pregnancy chronic 
kisspeptin-234 (KP-234) administration had no significant effect on glucose tolerance; however, at day 16 of pregnancy mice 
treated with KP-234 had significantly impaired glucose tolerance following i.p. glucose administration (2 g/kg) when com-
pared with untreated pregnant controls, as determined by both comparison of individual time points (2-way repeated-mea-
sures ANOVA; 60 minutes P = 0.022; 90 minutes P = 0.046) and (B) glucose AUC over the course of the test (1-way ANOVA, P 
= 0.031). (C) Blocking endogenous kisspeptin signaling with KP-234 did not have any effect on fasting plasma insulin levels 
at either day 10 or day 16 of pregnancy. At day 16 chronic KP-234 treatment resulted in significantly reduced insulin release in 
response to i.p. glucose administration (2  g/kg) after 30  minutes when compared with pregnant controls (1-way ANOVA, P 
= 0.009). A similar trend was observed at day 10; however, this was not significant. (D) KP-234 had no effect on the plasma 
glucose response to i.p. insulin administration (0.75 IU/kg) when compared to untreated controls at either day 12 or day 18 or 
pregnancy, through both comparison of individual time points and (E) glucose AUC. Mean ± SEM; n = 6; *P < 0.05 vs. control.
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observed in the mean area of  individual β cells, suggesting that deletion of  β cell GPR54 has no effect on 
pregnancy-induced hypertrophy (Figure 5E).
Circulating kisspeptin and glucose tolerance in pregnant women. Our studies in a cohort of  pregnant women 
further support a role for circulating placental kisspeptin in β cell adaptive responses to pregnancy, as 
shown in Figure 6. Under basal (fasting) conditions there was a significant, albeit weak, positive correla-
tion between kisspeptin and β cell secretory function, as assessed by Homeostatic Model Assessment 2–% 
β cell function (HOMA2-%β) (Figure 6G), although there was no significant correlation with fasting insu-
lin (Figure 6B). There was a highly significant medium-strength positive correlation between kisspeptin 
and oral glucose–stimulated insulin levels, as assessed by insulin AUC (Figure 6F). There was a highly 
significant medium-strength positive correlation between kisspeptin and serum insulin at 60 minutes after 
oral glucose load (Figure 6D), with a trend toward significance at 10 minutes (Figure 6C) and no signif-
icant correlation at 120 minutes (Figure 6E). There was a slight negative correlation between kisspeptin 
and fasting plasma glucose (r2 = –0.064; P = 0.016), with no significant correlations at 10 minutes, 60 
minutes, or 120 minutes (Supplemental Figure 5), suggesting the positive correlations between kisspeptin 
and insulin are not secondary to higher circulating glucose levels. There were no significant correlations 
between kisspeptin and Homeostatic Model Assessment 2–insulin resistance (HOMA2-IR) (Figure 6H) or 
the Matsuda index (Figure 6I), suggesting the positive correlations between kisspeptin and insulin are not 
secondary to altered insulin resistance.
In this cohort, 28.6% of  women had GDM. There were no significant differences in age, ethnicity, mul-
tiple pregnancy, gestation, number of  previous pregnancies, BMI, or blood pressure between women with 
and without GDM (Supplemental Table 1). However, women with GDM had significantly lower plasma 
kisspeptin levels than women without GDM (Figure 6A).
The reported correlations are for all pregnant women, both with and without GDM. Correlation 
coefficients were also calculated for women with and without GDM separately, and r2 values for the 
independent groups were similar to those for the combined data. The correlation observed between 
kisspeptin and HOMA2-%β was no longer significant when comparing women with GDM alone; how-
ever, this is most likely due to the smaller n value in the GDM group and the initial weak correlation. 
Figure 3. Effects of β cell GPR54 deletion on islet function in vitro. 
(A) There were no significant differences in islet insulin content 
between β cell GPR54–/– mice and any control groups (Cre+/TMX–, 
Cre–/TMX+, and Cre–/TMX–). Mean ± SEM, n = 9. (B) In static incuba-
tion experiments there was no significant difference in the insulin 
secretory response to physiological glucose concentrations between 
β cell GPR54–/– and Cre+/TMX– islets. (C) In perifusion experiments 
there was no significant difference in basal insulin secretion at 2 
mM glucose or first- or second-phase insulin secretion in response 
to 20 mM glucose in β cell GPR54–/– compared to Cre+/TMX– islets. 
Exposure of Cre+/TMX– islets to kisspeptin (1 μM, 30–50 minutes) 
resulted in a sustained enhancement of second-phase insulin secre-
tion for the duration of kisspeptin administration. However, in β 
cell GPR54–/– islets this response was transient and not maintained 
beyond 10 minutes as determined by comparison of individual 
time points and (D) AUC over 10-minute phases of the perifusion 
(2-tailed Student’s t test; KP — prolonged response; P = 0.007). 
Mean ± SEM; n = 8 (A); n = 7–8 (B); n = 4 (C and D); data representa-
tive of experiments conducted 2–3 times; *P < 0.05.
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All other correlations that were significant in the combined data were also significant for women with 
and without GDM independently.
In summary, in pregnant women higher plasma kisspeptin levels are associated with enhanced insulin 
secretion, particularly after oral glucose load, and lower levels of  plasma kisspeptin are associated with 
diagnosis of  GDM.
Discussion
Pregnancy represents a unique physiological state in which the islet β cells are exposed to very high levels 
of  circulating kisspeptin for a prolonged period, and we have here demonstrated that placentally derived 
kisspeptin is involved in β cell adaptations to pregnancy. Chronic elevations in circulating kisspeptin in virgin 
mice improved glucose tolerance as a consequence of  enhanced glucose-induced insulin secretion, consistent 
with previous in vitro studies of  a direct stimulatory effect of  β cell GPR54 activation on insulin secretion (7). 
The significant effects of  exogenous kisspeptin on glucose tolerance in nonpregnant mice were only apparent 
between 15 and 30 minutes after glucose administration, most likely because the normal control of  blood glu-
cose leaves little room for improvement, but the chronic kisspeptin treatment had marked effects to enhance 
glucose-induced insulin secretion in vivo. During murine pregnancy, pharmacological blockade of  GPR54 
resulted in impaired glucose tolerance as a consequence of  reduced glucose-induced insulin secretion. In nor-
mal mouse pregnancy, glucose tolerance is progressively impaired from mid-pregnancy (days 10–12) to late 
pregnancy (day 16–18) and associated with increased peripheral insulin resistance. Thus, pharmacological 
blockade of  GPR54 induced a mild impairment of  glucose tolerance at mid-pregnancy, which progressed to 
a more pronounced phenotype by late pregnancy, suggesting a progressive role for endogenous kisspeptin in 
mediating β cell adaptations to pregnancy-induced insulin resistance. This is consistent with the development 
Figure 4. Glucose tolerance in female β cell GPR54–/– mice. (A) There was no significant difference in glucose tolerance between nonpregnant adult 
female β cell GPR54–/– mice and any of the female control groups (Cre+/TMX–, Cre–/TMX+, and Cre–/TMX–). Similarly, the β cell GPR54–/– mice did not have 
(B) significantly altered plasma insulin levels, either fasted or after glucose, or (C) any change in insulin resistance when compared to any control group. (D) 
At day 16 of pregnancy β cell GPR54–/– mice had significantly impaired glucose tolerance at 15 and 30 minutes after glucose administration (2-way repeat-
ed-measures ANOVA; 15 minutes P = 0.028; 30 minutes P = 0.014) and (E) glucose AUC over the course of the test when compared with all control groups 
(1-way ANOVA; 0–120 minutes AUC P = 0.02; 0–60 minutes AUC P = < 0.001). (F) Pregnant β cell GPR54–/– mice did not have significantly altered basal 
fasting plasma insulin levels at day 16 of pregnancy; however, GPR54 knockdown did result in significantly reduced insulin release in response to i.p. glu-
cose administration (2 g/kg) after 30  minutes when compared with all controls (1-way ANOVA, P = 0.045). (G) Pregnant β cell GPR54–/– mice did not have 
significantly different insulin sensitivity either at any individual time point or in (H) glucose AUC. Mean ± SEM; n = 7–9 (A–C); n = 7–12 (D–H); *P < 0.05.
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of the mouse placenta, which becomes fully functional only around days 7–9 (27), suggesting that levels of  
circulating kisspeptin are unlikely to be elevated before this stage, with a subsequent progressive increase in 
circulating kisspeptin for the remainder of  the pregnancy, as has been reported during human pregnancy (17). 
The precise changes in circulating levels of  kisspeptin in rodent pregnancy have not been clearly established 
because of  continuing difficulties in developing accurate and specific rodent assays. However, rodent placenta 
expresses increasing levels of  kisspeptin mRNA through pregnancy (18–20), consistent with observations in 
humans, suggesting placental release of  kisspeptin into the maternal circulation.
The pharmacological data were supported by our observations using a β cell–specific GPR54-knock-
out mouse model. Hypothalamic GPR54 plays a critical role in maintaining reproductive function, so the 
B6.Cg-Tg(Ins1-cre/ERT)1Lphi/J (MIP-CreERT) line was selected to avoid the off-target hypothalamic 
Cre expression that is a characteristic of  the PDX1-Cre and RIP-Cre lines (28, 29). Although β cell–specific 
GPR54-knockout mice have been previously reported (13), they have not previously been studied during 
pregnancy. Validation of  the β cell GPR54–/– mice demonstrated a tissue-specific 70% reduction in islet 
GPR54 mRNA expression, with no detectable leakage in the hypothalamus (see Supplemental Figure 3). 
This reduction in GPR54 mRNA expression is consistent with other inducible knockout models, where 
100% gene knockout is not typically observed. Also, there is some controversy regarding whether GPR54 
is also expressed in islet α cells, with some previous studies suggesting it is expressed (4) and others finding 
it absent (13). If  GPR54 is present in islet endocrine cells other than β cells, then this would not be deleted 
in the β cell GPR54–/– mice, resulting in an underestimation of  GPR54 knockdown based on whole islet 
expression. In vitro studies in isolated islets confirmed that GPR54 knockdown had no effect on insulin 
content or on glucose-induced insulin secretion. Kisspeptin treatment of  β cell GPR54–/– islets did still 
induce a brief, transient potentiation of  insulin secretion, which may be consistent with the presence of  
residual GPR54 expression in the islets. However, kisspeptin did not maintain elevated insulin release in β 
cell GPR54–/– islets, suggesting that the effects are significantly attenuated in β cell GPR54–/– islets.
Figure 5. Effects of deletion of β cell GPR54 on pregnant β cell mass. Representative illustrative images of 
immunostaining for the measurement of β cell proliferation in pregnant (A) β cell GPR54–/– and (B) Cre+/TMX– islets 
showing merged BrdU staining (shown in green) and insulin staining (shown in red). Scale bars: 100 μm. (C) β cell 
GPR54–/– mice administered BrdU from days 10–18 of pregnancy had significantly reduced levels of BrdU labeling 
compared with pregnant Cre+/TMX– mice (2-tailed Student’s t test, P = 0.041). At day 18 of pregnancy there was no 
significant difference in either (D) mean overall islet area or (E) size of individual β cells between β cell GPR54–/– and 
Cre+/TMX– mice. Mean ± SEM; n = 6 (C–E); *P < 0.05.
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Based on the GPR54 blockade studies, β cell GPR54–/– mice were assessed during late pregnancy (days 
16–18) to maximize any metabolic phenotype. As expected, pregnant β cell GPR54–/– mice had significantly 
impaired glucose tolerance during late pregnancy as a consequence of reduced glucose-induced insulin secretion, 
in accordance with the pharmacological studies and supporting a β cell–specific action of placental kisspeptin to 
regulate glucose tolerance. However, no differences in placental weight, pup weight, or pup length were observed 
between β cell GPR54–/– mice and controls (Supplemental Figure 4, B–D). The absence of macrosomia suggests 
that despite the significant glucose intolerance, loss of β cell GPR54 signaling is not sufficient to induce GDM.
These studies used several controls to avoid any potentially confounding factors associated with the 
inducible transgene. Thus, the MIP-CreERT mouse has been reported to exhibit inappropriate human 
growth hormone expression in β cells, leading to increased islet serotonin levels (30–32), an effect that has 
so far been demonstrated only in males and that is relatively small compared with the normal increases in 
islet serotonin seen during pregnancy (3, 33). Nonetheless, we used Cre+ control mice to demonstrate that 
the transgene itself  had no effect on glucose tolerance in pregnant or nonpregnant female mice. Tamoxifen 
is a selective estrogen receptor modulator that can disrupt female reproductive cycles (34) and affect glucose 
tolerance through effects on lipid metabolism (30, 34, 35). To minimize these confounding effects, mice 
were left for 6 weeks following TMX administration, by which time animals had regained fertility and no 
TMX-dependent effects on glucose tolerance were detectable.
In addition to enhanced secretory responsiveness to glucose, β cells also adapt to pregnancy by 
increasing their functional β cell mass, through a combination of  an increased rate of  proliferation and 
Figure 6. Relationships between kisspeptin and insulin response to oral glucose and presence of GDM in pregnant 
women. (A) In pregnant women undergoing a routine 75-g oral glucose tolerance test (OGTT), women with gestational 
diabetes mellitus (GDM, International Association of Diabetes and Pregnancy Study Groups [IADPSG] 2010 criteria, 
n = 26) had significantly lower kisspeptin than women without GDM (n = 62; *P = 0.0022; 2-tailed Student’s t test). 
(B) Analyzing all pregnant women (n = 91) there was no significant correlation between kisspeptin levels and fasting 
serum insulin, but there was a significant positive correlation between kisspeptin and serum insulin at 60 minutes (D; 
r2 = 0.1757; P < 0.0001) and between kisspeptin and AUC serum insulin over the OGTT (F; r2 = 0.1279; P = 0.0013). There 
was no significant correlation between kisspeptin and serum insulin at 10 minutes (C) or 120 minutes (E). There was a 
significant positive correlation between kisspeptin and HOMA2-%β (G; r2 = 0.0656, P = 0.0411), but no significant cor-
relations between kisspeptin and HOMA2-IR (H) or the Matsuda index (I). Women diagnosed with GDM are represent-
ed by white markers; women without GDM are represented by black markers. Pearson product-moment correlation 
coefficient was used for analyzing correlation data, and presented correlation data are based on all women. Correlation 
coefficient lines denote a significant correlation between variables.
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β cell hypertrophy in rodents. This β cell expansion occurs primarily after placentation in rodents over 
a relatively short and well-defined time span and is reversible postpartum, consistent with placental 
signals playing a major role in informing the β cells of  the gestational stage via circulating mediators. 
It is well established that the lactogenic hormones, prolactin and placental lactogen, play a key role in 
metabolic adaptations during pregnancy, but lactogenic hormones are unlikely to account for all the β 
cell adaptive responses; other factors have been implicated in the successful islet adaptation to pregnan-
cy (36). Our observations of  reduced β cell proliferation in pregnant β cell GPR54–/– mice suggest that 
placental kisspeptin does play a physiological role in regulating β cell mass to compensate for the preg-
nancy-induced insulin resistance. However, the reduced proliferative rate in pregnant β cell GPR54–/– 
islets is not associated with a corresponding reduction in β cell hypertrophy and overall is not sufficient 
to translate into a significant overall reduction in β cell mass. It might be expected that the reduced 
rate of  proliferation would result in a corresponding reduction in mean islet area. Although there is a 
trend toward reduced islet area in the pregnant β cell GPR54–/– mice, it is likely that the relatively small 
change in proliferation rate combined with the natural variability in islet area means that any effect on 
islet area is not sufficient to achieve significance. It is worth noting that, though significant, the effects 
of  β cell GPR54 knockdown on proliferation are not as dramatic as the effect observed in response to β 
cell–specific knockdown of  the prolactin receptor (37). Thus, although placental kisspeptin may play a 
contributory role in the upregulation of  β cell proliferation during pregnancy, it does not appear to be a 
major driver of  this response to the extent of  the lactogenic hormones.
Our mouse data suggest that kisspeptin signaling via GPR54 facilitates metabolic control by enhancing the 
insulin secretory responses of the β cells and to some extent by increasing the number of β cells. Less informa-
tion is available about the regulation of the β cell adaptation to human pregnancy, particularly with regard to 
β cell mass. Postmortem studies indicate that β cell mass certainly increases in human pregnancy, though the 
underlying mechanisms are unclear and may differ from rodent pregnancy (38). Regardless, the core character-
istics involved in the β cell adaptation in rodents appear to be conserved to some extent in human pregnancy.
There is great interest in determining whether signals identified in rodent pregnancy are also involved 
in regulating human β cells. Our previous studies suggested that the effects of  kisspeptin in pregnancy may 
translate to humans, given that kisspeptin is able to potentiate glucose-stimulated insulin secretion from 
human islets in vitro (6). Our studies in pregnant women undergoing OGTTs as part of  their routine clinical 
care suggest that placental kisspeptin may have a similar function in humans to that revealed in our mouse 
models. In accordance with our animal data, glucose-induced insulin secretion was positively correlated 
with plasma kisspeptin. This is consistent with placentally derived kisspeptin exerting an “incretin-like” 
(39) action in pregnancy to facilitate greater β cell insulin secretion in response to glucose ingestion to com-
pensate for pregnancy-associated insulin resistance. We also observed a weak positive correlation between 
kisspeptin and basal β cell secretory function as assessed by HOMA2-%β in pregnant women, though there 
was no significant correlation between kisspeptin and fasting insulin levels in either pregnant women or 
in animal studies. In addition, we demonstrated that women with GDM had significantly lower plasma 
kisspeptin levels than women without GDM, which supports a previous report of  lower mean kisspeptin 
in GDM (40). Low placental production of  kisspeptin has been suggested as a risk factor for preeclampsia 
and early pregnancy bleeding (41, 42), and it is of  interest that GDM is a risk factor for preeclampsia (43). 
These data are constrained by the obvious ethical limits of  intervening during human pregnancy, and there 
should be some caution when drawing conclusions from correlative results. However, it is noteworthy that 
all the significant correlations observed in these pregnant women are between kisspeptin levels and markers 
of  β cell function (e.g., robust insulin response to glucose, HOMA2-%β), with no correlations observed 
between kisspeptin and other markers (e.g., HOMA2-IR). Considered with our animal data, this suggests 
reduced placental kisspeptin production, with consequent impaired kisspeptin-dependent β cell compensa-
tion, may be a factor in the development of  GDM in humans.
It is less clear what, if  any, role kisspeptin plays in metabolic control outside of pregnancy because we 
detected no phenotype in nonpregnant β cell GPR54–/– mice. Previous studies have reported both potential 
beneficial and inhibitory effects of kisspeptin on glucose tolerance in nonpregnant, usually male, mice (13, 14, 
44), but these effects may not be β cell specific and are most often observed in metabolically stressed animals. 
Furthermore, a recent human study reports that elevated plasma kisspeptin correlates with impaired glucose 
tolerance in both male and female, nonpregnant, nondiabetic individuals (45), though it is well established that 
plasma kisspeptin levels are several thousand–fold lower outside of pregnancy (17). Although we cannot rule out 
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that kisspeptin may play a role in regulating β cell function outside of pregnancy, the impaired glucose tolerance 
seen in these β cell GPR54–/– mice appears to be a pregnancy-specific phenomenon. It has been suggested that 
the different-length kisspeptin peptides may have differing effects, and it is worth noting that the placenta releas-
es all forms of kisspeptin into the circulation. There is a precedent for the differing forms of kisspeptin having 
specific effects because kisspeptin-10, but not longer forms of kisspeptin, plays a role in trophoblast invasion 
(46). Several studies have put forward the hypothesis that higher concentrations of kisspeptin may potentiate 
glucose-induced insulin release while lower concentrations may be inhibitory (47). As such, our findings in preg-
nant women and the β cell GPR54–/– mouse model do not necessarily contradict previous studies demonstrating 
inhibitory effects of kisspeptin on insulin secretion but support the possibility that kisspeptin may have different 
effects under different conditions, though the precise mechanisms involved remain to be established.
Together, our data are consistent with placentally derived kisspeptin in the maternal circulation exert-
ing an effect on maternal β cells during pregnancy to facilitate enhanced glucose-induced insulin secretion 
and increase β cell mass to compensate for maternal insulin resistance, thus avoiding overt hyperglycemia. 
The expression of  GPR54 by β cells allows them to detect elevations in kisspeptin during pregnancy, 
informing them about the state of  pregnancy and enabling them to respond to the peculiar metabolic 
demands of  pregnancy. We have recently reported that mouse placenta expresses about 80 ligands for β 
cell GPCRs (48), suggesting that kisspeptin may be one of  many novel placental signals regulating β cell 
function during pregnancy.
In conclusion, we have demonstrated an important role for placental kisspeptin in amplifying glu-
cose-induced insulin secretion across species, consistent with a physiological role for kisspeptin in the β cell 
adaptation to pregnancy. Our data in pregnant women, considered with our animal data, suggest reduced 
placental kisspeptin production, with consequent impaired kisspeptin-dependent β cell compensation, may 
be a factor in the development of  GDM in humans. Kisspeptin may offer a promising biomarker for devel-
oping GDM, or a tractable target for therapeutic intervention, or both.
Methods
Animals. Female ICR mice (Envigo, Bicester, United Kingdom) at 8 weeks of  age were used for in vivo 
pharmacological studies. The β cell GPR54–/– mouse model was generated on a C57BL/6 background 
using Cre-lox recombination. GPR54-loxP mice (49) (obtained from M. Tena-Sempere, University of  Cor-
doba, Spain) were crossbred with MIP-Cre/ERT mice (ref. 50; Jackson Labs). TMX was administered to 
induce GPR54 knockdown in the relevant mice at 8 weeks of  age through daily i.p. injection (100 μL of  
20 mg/mL TMX in peanut oil, MilliporeSigma) for 4 consecutive days. Mice were then left for 6 weeks 
to allow TMX washout. Further details on the validation of  the β cell GPR54–/– mice are available within 
Supplemental Figure 2.
All animals were housed under controlled conditions (14-hour light/10-hour dark, lights on at 0700 
hours, temperature at 22 ± 2°C) and provided food and water ad libitum.
In vivo studies. For pregnant mice, females were housed with a male and checked daily for the presence 
of  a vaginal plug. The day a vaginal plug was observed was designated day 0 of  pregnancy. Age-matched 
female mice were used for studies in nonpregnant animals.
For pharmacological studies, animals were implanted with a subcutaneous osmotic minipump (Alzet) 
under isoflurane anaesthesia. Minipumps contained either 1 mM of  kisspeptin-10 (Alta Biosciences) or 2 
mM of  the GPR54 antagonist kisspeptin-234 (51) (MilliporeSigma). In pregnant animals minipumps were 
implanted at either day 2 or day 8 of  pregnancy. Osmotic minipumps released either 0.25 nmol/h kiss-
peptin-10 or 0.4 nmol/h kisspeptin-234 at an infusion rate of  0.4 nmol/h.
For glucose tolerance tests mice were fasted for 6 hours and administered glucose (2 g/kg) via i.p. 
injection. Blood samples (~1 μL) were taken by tail prick for the measurement of  blood glucose levels. 
Larger blood samples were taken from the tail vein for the measurement of  plasma insulin levels. Plasma 
insulin levels were subsequently measured using a mouse ultrasensitive insulin ELISA kit (Mercodia).
For insulin tolerance tests mice were also fasted for 6 hours and were administered insulin (0.75 
IU/kg, MilliporeSigma) via i.p. injection. Small blood samples were taken by tail prick for the measure-
ment of  blood glucose levels.
In β cell GPR54–/– mice, from day 10 of  pregnancy onward, BrdU (1 mg/mL) was administered in the 
drinking water to label proliferating cells. Following the insulin tolerance test animals were culled and the 
pancreas collected for histology.
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β cell GPR54–/– in vitro studies. Islets of  Langerhans were isolated from female β cell GPR54–/– and con-
trol mice by collagenase digestion of  the exocrine pancreas. Islets were incubated at 37°C in RPMI (supple-
mented with 10% fetal calf  serum, 2 mM glutamine, and 100 units/mL penicillin/0.1 mg/mL streptomy-
cin) for at least 24 hours before use.
Insulin secretion from mouse islets was assessed either using a temperature-controlled perifusion 
apparatus or in static incubations of  islets. For perifusion experiments groups of  40 islets were perifused 
with a bicarbonate-buffered physiological salt solution (0.5 mL/min, 37°C) containing 2 mM glucose, 
2 mM CaCl2, and 0.5 mg/mL BSA and supplemented with treatments of  interest. Perifusate was col-
lected at 2-minute intervals for insulin content. For static incubations islets were preincubated in 2 mM 
glucose RPMI. Groups of  10 size-matched islets were incubated at 37°C for 1 hour in physiological salt 
solution as described above, supplemented with agents of  interest. After 1 hour samples were taken and 
assayed for insulin content. For islet insulin content, groups of  10 islets were transferred into acid-etha-
nol and sonicated. Insulin levels were determined using an in-house radioimmunoassay.
β cell mass analysis. Pancreas samples were fixed in 4% paraformaldehyde (MilliporeSigma) and 
embedded in paraffin wax. Sections (5 μm) were rehydrated followed by antigen retrieval with 2N 
hydrochloric acid for 20 minutes at 37°C and subsequent 0.05% trypsin solution (MilliporeSigma) for 
15 minutes at 37°C. Sections were incubated in blocking buffer (0.25% BSA, 0.25% Triton X-100 in 
PBS) before incubation with both a mouse monoclonal anti-BrdU antibody (1:100, MilliporeSigma, 
B8434) and guinea pig polyclonal anti-insulin antibody (1:200, Dako, A0564) for 2 hours at 37°C.
Alexa Fluor 488–conjugated donkey antimouse (1:100, Jackson ImmunoResearch) and Alexa Fluor 
594–conjugated donkey anti–guinea pig (1:100, Jackson ImmunoResearch) were used to visualize staining. 
A Nikon Eclipse TE2000-U microscope was used for acquiring images at original magnification ×200 
using a Nikon DS-Qi1MC camera.
Sections were analyzed from across the pancreas for each animal, and all islets on each section were 
analyzed. ImageJ image analysis software (NIH) was used to count the number of  BrdU+ β cells, total num-
ber of  β cells, and cross-sectional area for each islet.
Plasma kisspeptin and glucose tolerance in pregnant women. Pregnant women between 26 and 34 weeks’ gesta-
tion referred for an OGTT at King’s College Hospital as part of routine care were invited to participate. Wom-
en were referred for an OGTT if  they had GDM in a previous pregnancy, BMI at least 40 kg/m2, or random 
plasma glucose at least 6.7 mmol/L. Exclusion criteria were being unable to give informed consent and known 
major medical problems. One hundred women were recruited and data are presented for 91 women for whom 
blood samples were obtained. Further participant details are available within Supplemental Table 1.
Participants underwent a standard 2-hour 75-g OGTT with additional blood sampling. After over-
night fasting (>9 hours), an intravenous cannula was inserted in an arm vein for blood sampling, the 
participant drank 75 g glucose in 300 mL, and rested for 2 hours. Venous blood samples were taken 
before glucose consumption for the measurement of  plasma kisspeptin, plasma glucose, and serum insu-
lin. Further blood samples were taken at 10 minutes, 60 minutes, and 120 minutes for the measurement 
of  plasma glucose and serum insulin. For this research GDM was diagnosed according to the IADPSG 
criteria (52): 1 or more of  venous plasma glucose fasting ≥ 5.1 mmol/L, 60 minutes ≥ 10.0 mmol/L, or 
120 minutes ≥ 8.5 mmol/L. Weight, height, and blood pressure were measured.
Preparation and assay of  human samples. For plasma kisspeptin, 5-mL venous blood samples were collect-
ed into tubes containing EDTA (BD Vacutainer Blood Collection Tubes) (53). Samples were centrifuged at 
855 g for 10 minutes at 4˚C. Plasma was collected and stored at –80˚C until assay. Plasma kisspeptin was 
measured using a commercially available ELISA kit (Phoenix Pharmaceuticals Inc.). Peptide extraction was 
performed on all kisspeptin samples based on the manufacturer’s protocol (Phoenix Pharmaceuticals Inc.) 
and absorbances measured using a Chameleon plate reader.
For serum insulin, 5-mL venous blood samples were collected into SST tubes (BD Vacutainer Blood 
Collection Tubes) and allowed to stand for a minimum of  20 minutes at room temperature before centrif-
ugation at 855 g for 10 minutes at 4˚C. Serum was collected and stored at –80˚C until assay. Serum insulin 
levels were measured using a commercially available ELISA kit (Mercodia). The ELISA was performed 
according to the manufacturer’s instructions and absorbances measured using a Chameleon plate reader.
For plasma glucose measurement, 2-mL venous blood samples were collected into tubes containing 
Fluoride EDTA (BD Vacutainer Blood Collection Tubes). Samples were centrifuged at 855 g for 10 minutes 
at 4˚C. Plasma glucose was measured immediately using a YSI 2300 Stat Analyser (YSI Life Sciences).
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HOMA2-%β and HOMA2-IR were calculated using the HOMA2 calculator (version 2.2.3, specific insu-
lin) downloaded from http://www.dtu.ox.ac.uk/homacalculator/ on August 4, 2018 (54). Matsuda index was 
calculated using the online calculator available at http://www.mmatsuda.diabetes-smc.jp/MIndexsi.html on 
August 4, 2018, using time 0, 60, and 120 minutes data (55).
Statistics. All data are expressed as mean ± SEM. Each in vitro and in vivo study was repeated at 
least twice with consistent results. For comparison between 2 groups unpaired 2-tailed Student’s t test 
was used. For comparisons between 3 or more groups, a 1-way ANOVA was used followed by Tukey’s 
post hoc test. For analysis of  individual intraperitoneal glucose tolerance test and intraperitoneal insu-
lin tolerance test data points, 2-way repeated measures ANOVA was used, followed by Tukey’s where 
appropriate. For analysis of  correlations the Pearson product-moment correlation coefficient was used. 
Differences with P less than 0.05 were considered significant.
Study approval. All animal procedures were approved by the local King’s College London Animal 
Welfare and Ethical Review Board and were undertaken in accordance with United Kingdom Home 
Office Regulations.
The research in humans was conducted in accordance with the Declaration of  Helsinki (2013) and 
was approved by the London-Westminster Research Ethics Committee (13/LO/0539). Written informed 
consent was obtained from all participants.
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